In line with the practice in many Member States and in most international organisations based in Geneva, the CHIS will, as of 1 July 2017, reimburse infertility treatments to persons benefiting from its normal health insurance cover.
Such reimbursements are subject to: 1) prior approval by the third‑party administrator, UNIQA, upon presentation of a medical prescription and other relevant information; and 2) to a life‑time ceiling for expenses of 30,000 CHF.
These infertility treatments will be considered as pharmaceutical costs or medical treatments, to which the reimbursement rates of the General Rule will apply (note that the reimbursement bonus will not apply).
Treatments undertaken or paid before 1 July 2017 will be managed according to the current rules that are more restrictive.
For more information, do not hesitate to contact the third-party administrator of the CHIS: UNIQA (Tel.: 72730 / email@example.com).